Inventor
Weidong Liu
Inventor
Boulder, CO, US
Overview
Patents· 16 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds19%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations17%
A61KPreparations for medical, dental or toiletry purposes16%
C07BGeneral methods of organic chemistry10%
C30BSingle-crystal growth10%
H01LSemiconductor devices4%
H10KOrganic electric solid-state devices4%
Y02ATechnologies for adaptation to climate change4%
Y02PClimate change mitigation technologies in the production or processing of goods4%
C07KPeptides3%
PatentTitleYear
10,985,228Flexible display panel with reinforced insulating layer, method of manufacturing flexible display panel, and flexible display apparatus202110,985,225Organic light-emitting diode display substrate and method for manufacturing the same202110,930,518OLED substrate and manufacturing method thereof, display device and manufacturing method thereof202110,835,5331 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor202010,745,419Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile202010,729,678Preparation of and formulation comprising a MEK inhibitor202010,398,683Preparation of and formulation comprising a MEK inhibitor201910,329,288Process for preparing a compound20199,980,944Preparation of and formulation comprising a MEK inhibitor20189,598,376'Preparation of and formulation comprising a MEK inhibitor'20179,562,016'Preparation of and formulation comprising a MEK inhibitor'20179,382,212'Preparation of and formulation comprising a MEK inhibitor'20169,238,627'Preparation of and formulation comprising a MEK inhibitor'20168,648,087'N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases'20148,299,021'Macrocyclic inhibitors of hepatitis C virus replication'20127,829,665'Macrocyclic inhibitors of hepatitis C virus replication'2010Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2010–2012Patents assigned to INTERMUNE INC (2)· patent assignee history
2010–2020Based in Superior, CO, US· patent location history
2012–2014Patents assigned to LIU WEIDONG (2)· patent assignee history
2014–2020Patents assigned to ARRAY BIOPHARMA INC (11)· patent assignee history
2016–2017Patents assigned to NOVARTIS AG (4)· patent assignee history
2016–2020Based in Boulder, CO, US· patent location history
2020Based in Longmont, CO, US· patent location history
2021Patents assigned to BOE TECHNOLOGY GROUP CO LTD (3)· patent assignee history
2021Based in Beijing, CN· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ARRAY BIOPHARMA INC | 11 | 2014–2020 |
| NOVARTIS AG | 4 | 2016–2017 |
| BOE TECHNOLOGY GROUP CO LTD | 3 | 2021 |
| INTERMUNE INC | 2 | 2010–2012 |
| LIU WEIDONGself | 2 | 2012–2014 |
Locations
| Location | Patents | Span |
|---|---|---|
| Boulder, CO, US | 8 | 2016–2020 |
| Superior, CO, US | 4 | 2010–2020 |
| Beijing, CN | 3 | 2021 |
| Longmont, CO, US | 1 | 2020 |